Related references
Note: Only part of the references are listed.Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2012)
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B. Leal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma
Andrzej Hellmann et al.
CLINICAL PHARMACOKINETICS (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma
David I. Quinn et al.
CLINICAL PHARMACOKINETICS (2009)
Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study
Karthik Venkatakrishnan et al.
CLINICAL THERAPEUTICS (2009)
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
Philippe Moreau et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
J Lundin et al.
BLOOD (2002)
Share Paper
